Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.49 |
| ▸ | CALCRL | Q16602 | 6/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959682 | 0.92 | SLC6A2 (0.54) | SLC6A2CAPN1CALCRLCTSBOPRM1 | |
| SCHEMBL29886892 | 0.87 | OPRM1 (0.47) | SLC6A2CAPN1OPRM1XIAPOPRD1 | |
| SCHEMBL30485547 | 0.86 | SLC6A2 (0.51) | SLC6A2CAPN1CALCRLOPRM1XIAP | |
| SCHEMBL29404832 | 0.86 | SLC6A2 (0.48) | SLC6A2CAPN1CALCRLXIAPRAMP1 | |
| SCHEMBL30525445 | 0.83 | CAPN1 (0.53) | SLC6A2CAPN1CALCRLCTSBOPRM1 | |
| SCHEMBL30485542 | 0.83 | SLC6A2 (0.48) | SLC6A2CAPN1CALCRLCTSBOPRM1 | |
| SCHEMBL3253682 | 0.83 | CAPN1 (0.51) | SLC6A2CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL3253690 | 0.83 | CAPN1 (0.51) | SLC6A2CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL22484305 | 0.83 | XIAP (0.50) | SLC6A2CALCRLXIAP | |
| SCHEMBL22484304 | 0.83 | XIAP (0.50) | SLC6A2CALCRLXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146066-A1 | STOICHIOMETRIC GAS VESICLE EXPRESSION SYSTEM AND RELATED CONSTRUCTS, GENETIC CIRCUITS, VECTORS, CELLS, HOSTS, COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2026-05-28 | — | — | US | disclosed |
| US-20250230446-A1 | GAS VESICLE EXPRESSION SYSTEMS, GAS VESICLE CONSTRUCTS AND RELATED GENETIC CIRCUITS, VECTORS, MAMMALIAN CELLS, HOSTS, COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2025-07-17 | — | — | US | disclosed |
| US-12241069-B2 | Gas vesicle expression systems, gas vesicle constructs and related genetic circuits, vectors, mammalian cells, hosts, compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20230357780-A1 | GAS VESICLE EXPRESSION SYSTEMS, GAS VESICLE CONSTRUCTS AND RELATED GENETIC CIRCUITS, VECTORS, MAMMALIAN CELLS, HOSTS, COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-11-09 | — | — | US | disclosed |
| US-11761008-B2 | Gas vesicle expression systems, gas vesicle constructs and related genetic circuits, vectors, mammalian cells, hosts, compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146066-A1 | STOICHIOMETRIC GAS VESICLE EXPRESSION SYSTEM AND RELATED CONSTRUCTS, GENETIC CIRCUITS, VECTORS, CELLS, HOSTS, COMPOSITIONS, METHODS AND SYSTEMS | EXOSC4, TIA1, GNAI2 | SLC6A2 3234/4885CAPN1 1873/4885CALCRL 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.